Page 108 - Read Online

Alqahtani et al. Hepatoma Res 2020;6:58 I http://dx.doi.org/10.20517/2394-5079.2020.49 Page 17 of 18

124. Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-coding RNAs and hepatitis C virus-induced hepatocellular carcinoma. Viruses
2018;10:591.
125. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts
to tumorigenic phenotype. J Virol 1996;70:4438-43.
126. Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma. Biology (Basel) 2013;2:304-16.
127. WHO. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016.2018; Available from: http://
origin.who.int/healthinfo/global_burden_disease/estimates/en/. [Last accessed on 22 Jul 2017]
128. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res 2014;110:79-93.
129. European Association for the Study of the Liver, European Association for the Study of the Liver. EASL Recommendations on Treatment
of Hepatitis C 2018. J Hepatol 2018;69:461-511.
130. Cooke GS, Andrieux-meyer I, Applegate TL, Atun R, Burry JR, et al. Accelerating the elimination of viral hepatitis: a lancet
gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol 2019;4:135-84.
131. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular
carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
132. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting
antiviral agents. Gastroenterology 2017;153:996-1005.e1.
133. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on
mortality in patients with advanced liver disease. Hepatology 2019;69:487-97.
134. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al; Rete Sicilia Selezione Terapia-HCV (RESIST-HCV). Incidence of
hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology
2018;155:411-21.e4.
135. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
136. Colombo M, Boccaccio V. HCV therapy and risk of liver cancer recurrence: who to treat? Nat Rev Gastroenterol Hepatol 2018;15:392-3.
137. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
138. Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, et al. Undefined/non-malignant hepatic nodules are associated with early
occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol 2020; doi: 10.1016/j.jhep.2020.03.030.
139. Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology 2012;142:1274-8.
140. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, et al. Microsatellite distribution and indication for locoregional therapy in small
hepatocellular carcinoma. Cancer 2005;103:299-306.
141. Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, et al. Effects of all-oral anti-viral therapy on HVPG and systemic
hemodynamics in patients with hepatitis C Virus-associated cirrhosis. Gastroenterology 2017;153:1273-83.e1.
142. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, et al. Association between aspirin use and risk of hepatocellular
carcinoma. JAMA Oncol 2018;4:1683-90.
143. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011;378:73-85.
144. Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, et al. Prevalence and burden of hepatitis D virus infection in the global population: a
systematic review and meta-analysis. Gut 2019;68:512-21.
145. Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication
of hepatitis delta virus-induced liver fibrosis. Gastroenterology 2007;132:343-57.
146. Park CY, Oh SH, Kang SM, Lim YS, Hwang SB. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB
signaling. Mol Cells 2009;28:49-55.
147. Williams V, Brichler S, Khan E, Chami M, Dény P, et al. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress. J
Viral Hepat 2012;19:744-53.
148. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, et al. Influence of hepatitis delta virus infection on morbidity and mortality
in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000;46:420-6.
149. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl
Cancer Inst 2012;104:790-2.
150. Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors,
and outcomes. J Hepatol 2015;63:586-92.
151. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor
for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629-38.
152. Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, et al. High serum levels of HDV RNA are predictors of cirrhosis and liver
cancer in patients with chronic hepatitis delta. PLoS One 2014;9:e92062.
153. Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, et al; Hepatitis Delta International Network. Clinical and virological
heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int
2018;38:842-50.
154. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J
Hepatol 2010;53:834-40.
155. Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, et al. Natural history of compensated viral B and D cirrhosis. Rom J